Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Prepaid Assets for 6 consecutive years, with $210566.0 as the latest value for Q3 2025.

  • Quarterly Prepaid Assets fell 25.04% to $210566.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $210566.0 through Sep 2025, down 25.04% year-over-year, with the annual reading at $826473.0 for FY2024, 275.98% up from the prior year.
  • Prepaid Assets for Q3 2025 was $210566.0 at Inhibikase Therapeutics, down from $682628.0 in the prior quarter.
  • The five-year high for Prepaid Assets was $1.5 million in Q4 2021, with the low at $52475.0 in Q1 2025.
  • Average Prepaid Assets over 5 years is $592827.2, with a median of $565301.0 recorded in 2022.
  • The sharpest move saw Prepaid Assets surged 2640.35% in 2021, then crashed 93.83% in 2025.
  • Over 5 years, Prepaid Assets stood at $1.5 million in 2021, then tumbled by 89.12% to $163452.0 in 2022, then surged by 34.48% to $219817.0 in 2023, then skyrocketed by 275.98% to $826473.0 in 2024, then crashed by 74.52% to $210566.0 in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $210566.0, $682628.0, and $52475.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.